AstraZeneca has officially announced the expansion of its collaboration with Immunai, a New York-based AI bioTechnology company, extending their partnership agreement through 2027. This strategic move underscores the phArmaceutical giant's commitment to leverAGIng advanced Artificial Intelligence to revolutionize drug discovery and development.
Deal Structure and Financial Scope
Under the terms of the expanded agreement, Immunai is eligible to receive up to $37.5 million across 2026 and 2027. This funding supports the continued utilization of Immunai’s proprietary platform within AstraZeneca’s oncology pipeline.
Technological Synergy: The Power of AMICA-OS
At the core of this collaboration is Immunai’s flagship platform, AMICA-OS. This advanced system is capable of analyzing CLInical immunology data at the single-cell level, providing unprecedented granularity in underStanding immune responses.
AstraZeneca will deploy this technology to enhance several critical areas of its oncology programs:
biomarker discovery: Identifying novel biological markers for early detection and treatment monitoring.
Patient Stratification: Precisely selecting patient populations most likely to respond to therapy.
Dose Optimization: Determining the most effective and safe dosage levels.
Mechanism-of-ACTion (MoA) Analysis: Deepening the understanding of how drugs interact with biological targets.
️ A History of Collaboration
This expansion builds upon a robust foundation of coOperation between the two entities:
2024: The initial agreement was established to integrate Immunai’s platform into oncology clinical programs.
2025: The scope of work was widened to include research into inflammatory bowel disease (IBD).
2026-2027: The current expansion focuses on deepening these capabilities to accelerate the delivery of transformative cancer therapies.
Comments & Questions (0)
No comments yet
Be the first to comment!